HOME >> MEDICINE >> NEWS
Nortran Pharmaceuticals Inc. and Hoechst Marion Roussel announce collaborativeagreement

Vancouver, Canada -- Nortran Pharmaceuticals Inc., the Canadian drug discovery company, and Hoechst Marion Roussel ("Hoechst"), the global pharmaceutical subsidiary of Hoechst AG, today announced the signing of a collaborative agreement in the area of cardiac arrhythmias. This collaboration will capitalize on the complementary expertise of the two companies in this area.

Under the terms of the agreement Nortran and Hoechst Marion Roussel will test investigational antiarrhythmic compounds developed by both companies. The companies will evaluate the pharmacological profiles of their compounds through the use of both companies' proprietary electrophysiological models and other preclinical tests.

"We are delighted to be working with a company of Hoechst Marion Roussel's calibre who have demonstrated their leadership in the field of cardiovascular therapeutics," commented Bob Rieder, President and Chief Executive Officer of Nortran. "We are confident that this agreement will give fresh impetus to the field of antiarrhythmic drugs and create new opportunities that will benefit both the pharmaceutical industry and ultimately patients with the condition."

Nortran recently presented findings of its preclinical research on atrial fibrillation at the European Congress of Pharmacology in Budapest. "The drugs we have developed exhibit unique pharmacological properties which may lead to a new class of antiarrhythmic drug, " said Greg Beatch, Vice President Research, Nortran. "The heart rate dependent activity of our molecules is the basis for safe, effective antiarrhythmic drugs. We are very excited about the potential for our new class of antiarrhythmics. Our collaboration with Hoechst Marion Roussel can only expedite our research program."

Hoechst Marion Roussel, a world leader in pharmaceutical-based health care, is dedicated to extending human life and enhancing its quality through the discovery, development, manufacture and sale of pharmaceutical produ
'"/>

Contact: Asa Zanatta
azanatta@ccpr.com
604-734-3663
Contemporary Communications
31-Aug-1999


Page: 1 2

Related medicine news :

1. Eyetech Pharmaceuticals, Inc. announces macugen data on treating macular degeneration
2. MetaPhore Pharmaceuticals initiates Phase I clinical trial of enzyme mimetic compound for oncology
3. Maret Pharmaceuticals presents promising Phase I/II clinical MARstem™ results at international symposium on new drugs in cancer therapy
4. NIH awards grant to MetaPhore Pharmaceuticals to study novel pain treatments
5. Aventis Pharmaceuticals Allegra (Fexofenadine Hcl) 30-Mg tablets now available to treat seasonal allergies, chronic hives in children 6 to 11 years
6. Pharmaceuticals and personal care products
7. Signal Pharmaceuticals Announces Positive Results In Preclinical Study Of Novel Drug Leads For Treatment Of Osteoporosis
8. Beyond Pharmaceuticals: Business And Academic Leaders Forecast The Future Of "Combinatorial Chemistry"
9. ONYX Pharmaceuticals Reports Phase II Clinical Trial Results At ASCO Meeting
10. The Gerontological Society of America announces Hartford Fellowship recipients
11. TB Alliance announces new drug discovery program with GlaxoSmithKline

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/11/2018)... ... ... Dr. Siavash Eftekhari, Oral and Maxillofacial Surgeon at Monarch Dental® in ... to deliver dental care in impoverished communities. Along with a team of fellow ... to help deliver care to over 550 individuals in need. , This outreach was ...
(Date:8/11/2018)... ATLANTA (PRWEB) , ... August 11, 2018 , ... ... winner of a Silver Stevie® Award in the Executive of the Year-Business category ... the world’s premier business awards program. All individuals and organizations worldwide – public ...
(Date:8/9/2018)... ... August 09, 2018 , ... ... by simplifying medication adherence monitoring with Smart-pill bottle and mobile applications, DoseSmart ... the App Orchard. , The DoseSmart medication management and medication adherence platform ...
(Date:8/7/2018)... ... August 07, 2018 , ... Sussex Vision Center, a multi-site optometry practice ... Sussex, OD, founded the practice in Coldwater, and over the last three decades has ... to offer comprehensive eye health services for patients of all ages. , “I ...
(Date:8/3/2018)... ... August 03, 2018 , ... On August 2, 2018 ... proceedings. Mark Sadaka of Sadaka Associates, LLC has been litigating Zostavax injuries ... before the Judicial Panel on Multidistrict Litigation for the thousands of people injured by ...
Breaking Medicine News(10 mins):
(Date:8/3/2018)... ... August 03, 2018 , ... Flexefits, a pioneer in direct -pay, direct access ... allowing participants in Direct Primary Care arrangements to keep HSA eligibility and permit DPC ... individual and $300 per family per month.) , “We are very pleased to see ...
(Date:8/2/2018)... ... ... UMD Professor Utpal Pal leads a team of investigators across multiple institutions ... of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), ... contribute to the spread of major diseases like Lyme disease. Pal is the project ...
(Date:8/2/2018)... ... August 02, 2018 , ... ... with customer relationship management (CRM), patient experience and provider communication solutions for ... Program for Health Information Service Providers (HISPs). DirectTrust is a ...
Breaking Medicine Technology:
Cached News: